BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Frerichs C, Smyth A. Treatment strategies for cystic fibrosis: what's in the pipeline? Expert Opinion on Pharmacotherapy 2009;10:1191-202. [DOI: 10.1517/14656560902928896] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Prayle AP, Smyth AR. From pipeline to patient: new developments in cystic fibrosis therapeutics. Expert Opinion on Pharmacotherapy 2013;14:323-9. [DOI: 10.1517/14656566.2013.769958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Treacy K, Tunney M, Elborn JS, Bradley JM. Mucociliary clearance in cystic fibrosis: physiology and pharmacological treatments. Paediatrics and Child Health 2011;21:425-30. [DOI: 10.1016/j.paed.2011.05.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Hadida S, Van Goor F, Dinehart K, Looker AR, Mueller P, Grootenhuis PD. Case History. Elsevier; 2014. pp. 383-98. [DOI: 10.1016/b978-0-12-800167-7.00024-9] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
4 Balch WE, Roth DM, Hutt DM. Emergent properties of proteostasis in managing cystic fibrosis. Cold Spring Harb Perspect Biol 2011;3:a004499. [PMID: 21421917 DOI: 10.1101/cshperspect.a004499] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 5.5] [Reference Citation Analysis]
5 Pezzulo AA, Stoltz DA, Hornick DB, Durairaj L. Inhaled hypertonic saline in adults hospitalised for exacerbation of cystic fibrosis lung disease: a retrospective study. BMJ Open 2012;2:e000407. [PMID: 22517980 DOI: 10.1136/bmjopen-2011-000407] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
6 Smyth AR, Cifelli PM, Ortori CA, Righetti K, Lewis S, Erskine P, Holland ED, Givskov M, Williams P, Cámara M, Barrett DA, Knox A. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis--a pilot randomized controlled trial. Pediatr Pulmonol 2010;45:356-62. [PMID: 20306535 DOI: 10.1002/ppul.21193] [Cited by in Crossref: 59] [Cited by in F6Publishing: 66] [Article Influence: 4.9] [Reference Citation Analysis]
7 Wang C, Protasevich I, Yang Z, Seehausen D, Skalak T, Zhao X, Atwell S, Spencer Emtage J, Wetmore DR, Brouillette CG, Hunt JF. Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis. Protein Sci 2010;19:1932-47. [PMID: 20687163 DOI: 10.1002/pro.480] [Cited by in Crossref: 71] [Cited by in F6Publishing: 69] [Article Influence: 6.5] [Reference Citation Analysis]
8 Nicolis E, Lampronti I, Dechecchi MC, Borgatti M, Tamanini A, Bezzerri V, Bianchi N, Mazzon M, Mancini I, Giri MG. Modulation of expression of IL-8 gene in bronchial epithelial cells by 5-methoxypsoralen. Int Immunopharmacol. 2009;9:1411-1422. [PMID: 19720161 DOI: 10.1016/j.intimp.2009.08.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
9 Sheikh Z, Ong HX, Pozzoli M, Young PM, Traini D. Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment? Expert Opinion on Orphan Drugs 2017;6:69-84. [DOI: 10.1080/21678707.2018.1409110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Rada B. Interactions between Neutrophils and Pseudomonas aeruginosa in Cystic Fibrosis. Pathogens 2017;6:E10. [PMID: 28282951 DOI: 10.3390/pathogens6010010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]